Last reviewed · How we verify
NCT03813394: 2018/00947
Bevacizumab and Pembrolizumab Combination in Platinum-resistant Recurrent/Metastatic NPC
Phase 1, PHASE2 trial testing pembrolizumab in Locally Recurrent Cancer in 48 participants. Participants enrolled and being followed up; not accepting new ones.
31 July 2024
Quick facts
| Lead sponsor | National University Hospital, Singapore |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 48 |
| Start date | 1 May 2019 |
| Primary completion | 31 July 2024 |
| Estimated completion | 1 June 2025 |
| Sites | 1 location across Singapore |
Drugs / interventions tested
- pembrolizumab (pembrolizumab) — full drug profile →
- bevacizumab (Bevacizumab-Bvzr) — full drug profile →
Conditions studied
- Locally Recurrent Cancer — all drugs for Locally Recurrent Cancer →
- Metastatic Nasopharyngeal Cancer — all drugs for Metastatic Nasopharyngeal Cancer →
Sponsor
National University Hospital, Singapore
Who can join
Adults 21 to 99, any sex, with Locally Recurrent Cancer or Metastatic Nasopharyngeal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single center, randomized, phase Ib/II open-label study of pembrolizumab (pembro or MK-3475) with or without bevacizumab in patients with recurrent non-curable or metastatic nasopharyngeal carcinoma (NPC).
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Neoantigens: promising targets for cancer therapy.
Xie N, Shen G, Gao W, Huang Z, et al · · 2023 · cited 713× · PMID 36604431 · DOI 10.1038/s41392-022-01270-x -
Normalization of the tumor microenvironment by harnessing vascular and immune modulation to achieve enhanced cancer therapy.
Choi Y, Jung K. · · 2023 · cited 100× · PMID 37907742 · DOI 10.1038/s12276-023-01114-w -
Targeting the signaling in Epstein-Barr virus-associated diseases: mechanism, regulation, and clinical study.
Cao Y, Xie L, Shi F, Tang M, et al · · 2021 · cited 86× · PMID 33436584 · DOI 10.1038/s41392-020-00376-4 -
Nasopharyngeal carcinoma: current views on the tumor microenvironment's impact on drug resistance and clinical outcomes.
Liu H, Tang L, Li Y, Xie W, et al · · 2024 · cited 85× · PMID 38254110 · DOI 10.1186/s12943-023-01928-2 -
Current status and advances of immunotherapy in nasopharyngeal carcinoma.
Xu JY, Wei XL, Wang YQ, Wang FH. · · 2022 · cited 62× · PMID 35547095 · DOI 10.1177/17588359221096214 -
Immune checkpoint inhibitors in the treatment of virus-associated cancers.
Gao P, Lazare C, Cao C, Meng Y, et al · · 2019 · cited 47× · PMID 31182108 · DOI 10.1186/s13045-019-0743-4 -
Epstein-Barr Virus Epithelial Cancers-A Comprehensive Understanding to Drive Novel Therapies.
Han S, Tay JK, Loh CJL, Chu AJM, et al · · 2021 · cited 42× · PMID 34956172 · DOI 10.3389/fimmu.2021.734293 -
Pembrolizumab with or without bevacizumab in platinum-resistant recurrent or metastatic nasopharyngeal carcinoma: a randomised, open-label, phase 2 trial.
Chong WQ, Low JL, Tay JK, Le TBU, et al · · 2025 · cited 13× · PMID 39826567 · DOI 10.1016/s1470-2045(24)00677-6
Verify or expand the search:
- PubMed search for NCT03813394
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of pembrolizumab
Trials testing the same drug.
- NCT07223424 — Patient Preference for Subcutaneous vs. Intravenous Immune Therapy · Phase 2 · recruiting
- NCT06899126 — Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-sm · Phase 3 · recruiting
- NCT06161545 — Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcino · Phase 2 · recruiting
- NCT05879484 — Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Ca · Phase 1, PHASE2 · withdrawn
- NCT06682806 — A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 · Phase 2 · terminated
Other National University Hospital, Singapore trials
Trials by the same sponsor.
- NCT06027983 — Chimeric Receptor T Cells With Trastuzumab in HER2+ Advanced Breast Cancer and Other Solid Tumors · Phase 1, PHASE2 · not yet recruiting
- NCT07460505 — Mandibular Advancement to Reduce Ventricular Load and Improve Quality-of-life in Heart Failure · NA · not yet recruiting
- NCT07319676 — Antigen Targeted T Cell Therapy for Relapsed/Refractory B Cell Lymphomas · Phase 1, PHASE2 · recruiting
- NCT06983769 — CPAP vs MAD for OSA in Patients With Cognitive Impairment. A Randomized Clinical Trial · NA · recruiting
- NCT07091175 — Dupilumab Therapy in Nephrotic Syndrome in Children · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03813394 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National University Hospital, Singapore
- Last refreshed: 22 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03813394.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing